In rats with high-fat-diet-induced NASH, celecoxib, a selective COX2 inhibitor, significantly reduces hepatic lipid accumulation and improves insulin resistance (Tian et al., 2014). Here, PTGS2 is linked to metabolic dysfunction-associated steatohepatitis.